Manojkumar Bupathi, MD, MS

Manojkumar Bupathi, MD, MS, is medical oncologist at Rocky Mountain Cancer Centers. He specializes in solid tumors with an advanced subspecialty expertise in breast cancers and genitourinary cancers

Articles by Manojkumar Bupathi, MD, MS

Integrating Frontline Biomarkers and Multidisciplinary Teams in Prostate Cancer

ByManojkumar Bupathi, MD, MS

September 15th 2026

Manojkumar Bupathi, MD, MS, discusses the changes that biomarker-based treatment brings to hormone-sensitive prostate cancer.

Rewriting the Playbook: How Biomarker-Driven Therapy Is Transforming Metastatic Prostate Cancer Care

ByManojkumar Bupathi, MD, MS,Jonah Feldman

September 11th 2026

For Prostate Cancer Awareness Month, Manojkumar Bupathi, MD, MS, examines how oncologists are changing practice after 4 key FDA approvals and a trend toward biomarker-driven therapy.

Four Approvals Reflect Growth in Hormone-Sensitive Prostate Cancer Treatment

ByManojkumar Bupathi, MD, MS

September 10th 2026

Manojkumar Bupathi, MD, MS, discusses the key trials that have made a splash in prostate cancer in the last year.

Supporting Community Oncologists in a GU Research Era

ByChandler H. Park, MD,Manojkumar Bupathi, MD, MS,Benjamin Garmezy, MD

January 21st 2026

Explore the vital role of community oncology in GU cancer treatment, bridging research and real-world applications for better patient care.

RCC Treatment Selection Should Incorporate Patient Discussion and Goals

ByManojkumar Bupathi, MD, MS

July 8th 2025

Manojkumar Bupathi, MD, MS, discusses physician perspectives on treatment selection for frontline metastatic renal cell carcinoma (RCC) from a Case-Based Roundtable event.

Long-Term Cabozantinib/Nivolumab Data Show Improved Survival in RCC

ByManojkumar Bupathi, MD, MS

October 17th 2022

Manojkumar Bupathi, MD, MS, discusses the updated efficacy results of the CheckMate 9ER trial of cabozantinib plus nivolumab for patients with previously untreated advanced clear cell renal cell carcinoma.